What Happened?
New York, NY-based BrainStorm-Cell Appointed Netta Blondheim-Shraga as Vice President of Research and Development
About the Company
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.
About the Person
Netta Blondheim-Shraga is Vice President of Research and Development at BrainStorm Cell. Previously, Netta held various senior HR leadership roles in the industry.
Info Source
News
Short Profile